Corixa (company)
 | |
| biotechnology/pharmaceutical | |
| Successor | acquired by GlaxoSmithKline |
| Founded | 1994 in Seattle, Washington |
| Defunct | March 31, 2006 |
| Headquarters | Seattle, Washington |
Number of locations | 2 |
- This article is about the biotech corporation. For the style fly tying, see Fly lure. For the heteropteran bugs, see Corixidae.
Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.
The name Corixa comes from the true bug (Insecta: Hemiptera: Heteroptera) genus Corixa (family Corixidae, Water boatman), described by Geoffroy, in 1762.
On 12 July 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa. GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.
On 31 March 2006, Corixa's doors closed after over 11 years in business.
External links
- "Corixa Corporation - powering the immune system". Archived from the original on 2006-03-01.
Coordinates: 47°36′58″N 122°20′03″W / 47.615976°N 122.334242°W